Japanese gene therapy venture AnGes, Inc. has decided to withdraw an application for the full approval in Japan of its hepatocyte growth factor (HGF) gene therapy Collategene (beperminogene perplasmid), for severe peripheral vascular disease (PVD).
The product obtained Japanese conditional approval in 2019 and had been filed for full approval in 2023. But a post-marketing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?